Atopic Dermatitis

WAILEA, Hawaii — A proof-of-concept study of ASLAN004 found it to be safe and efficacious in treating moderate to severe atopic dermatitis, according to a poster presented at Maui Derm for Dermatologists.

Adults with moderate-to-severe atopic dermatitis treated with dupilumab had fewer and shorter hospitalizations related to the skin condition, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

WAILEA, Hawaii — Atopic dermatitis of the head and neck was improved in patients treated with lebrikizumab, according to a study presented at Maui Derm for Dermatologists.

The FDA approved cibinqo, an oral, once-daily JAK inhibitor, for the treatment of patients with moderate to severe atopic dermatitis, according to a press release.

The FDA approved Rinvoq, a selective JAK inhibitor, for the treatment of moderate to severe atopic dermatitis among patients aged 12 years and older, according to a press release.

Women with a history of asthma, atopic dermatitis and allergic rhinitis before conception demonstrated increased risk for peripartum mental disorders, according to a study published in Clinical and Translational Allergy.

Allergy and asthma treatment improved this year as the FDA approved multiple medications for new treatment. Here are the top developments for 2021 as reported by Healio.

The FDA has approved tralokinumab for the treatment of moderate to severe atopic dermatitis, LEO Pharma announced in a press release.

Both children and adults with atopic dermatitis showed disease improvement with minimal adverse outcomes after using a Staphylococcus aureus-based topical treatment, according to a study.

COVID-19 dominated 2021, as patients and providers balanced its treatment and prevention against their allergy and asthma needs.